Siegfried Inaugurates Pharma API plant in Minden
Siegfried has inaugurated a new large-scale API production facility at its German site in Minden.
API manufacturing
Lilly Deepens Lebanon Campus Investment with $4.5 Billion Commitment
Eli Lilly adds $4.5 billion to its Indiana manufacturing programme, funding a new genetic medicine facility and expanded API capacity at Lebanon, taking its total US investment since 2020 past $50 billion.
AbbVie to Invest $380 Million in Chicago to Further Expand US API Manufacturing
Investment marks continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
Siegfried to Acquire Small Molecules Drug Substance Capacity in the US
Siegfried signed binding agreements to acquire three drug substance sites in the US and Australia.
Agno Pharma Acquires US cGMP API Manufacturing Site
Agno Pharma acquired Actylis's Eugene, Oregon CDMO facility, formerly Cascade Chemistry, for small-molecule API development and manufacturing, thereby expanding its US footprint.
A Balanced Model for the Future of Life Sciences
Following the acquisition of MCE Pharma Brenntag is building a unique position in both traditional pharma and biopharma.
AbbVie Invests $195 Million in US API Production
AbbVie announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the US.
Cambrex Expands Swedish Drugs Facility
Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to be completed by November 2020.
